Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.

Management of metastatic renal cell cancer (mRCC) has undergone a paradigm shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct comparative data are inadequate to inform treatment decisions.